The Effect of Secreted IL-10 from Mesenchymal Stem Cell on Immune Checkpoint Molecules
Bisri T., Farhat F., Ilyas S., Munir D., Jusuf N.K., Sari M.I., Putra A., Muhar A.M.
Abstract
Background: Immunosuppression in sepsis is hypothesized to result from the increased expression of the immune checkpoint molecules programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1). PD-1 and PD-L1 blockade therapies have been reported to increase survival in septic animals. Currently, the interleukin (IL)-10 within mesenchymal stem cell (MSC) secretome is known for its immunomodulatory capacity. Objective: To study the effect of IL-10 within MSC secretome on the expression of immune checkpoints in the rat model of sepsis. Methods: We used 48 male Rattus norvegicus rats in this research and divided them into four groups: sham (rats without sepsis induction and treatment), control (sepsis-induced rats without treatment), T1 (sepsis-induced rats treated with 150 µL of secreted IL-10 from MSC), and T2 (sepsis-induced rats treated with 300 µL of secreted IL-10 from MSC). Forty-eight hours after sepsis induction, we terminated the rats and collected the blood to examine the PD-1 and PD-L1 expression levels. Results: We found a decrease in the relative expression of PD-1 in the septic rat group given 150 µL and 300 µL of secreted IL-10 from MSC compared to the control group, but the decrease was not significant. We also found a decrease in the relative expression of PD-L1 mRNA in the septic rat group given 150 µL and 300 µL of secreted IL-10 from MSC compared to the control group. Conclusion: Administering secreted IL-10 from MSC reduces the expression of PD-1 and PD-L1 in sepsis. These findings suggest that MSC secretome can improve the immunosuppression in sepsis.
Autoimmune complications of immunotherapy: pathophysiology and management
Bass A.R., Chan K.K.
Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei
Bancroft G.J., Biggart R., Hawrylowicz C.M., Kessler B., Kewcharoenwong C., Lertmemongkolchai G., Nithichanon A., Rinchai D.
The therapeutic potential of mesenchymal stem cells in COVID-19: Present and future
Putra I.B., Sari M.I., Wijaya D.W.
Immunological priming of mesenchymal stromal/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease via engagement of PD-1 ligands
Hackel A.
The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review
Ilyas S., Sari M.I.
Role of regulation of PD-1 and PD-L1 expression in sepsis
Ma T., Yu-Jing L., Zhang T.
A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction
Ayala A., Chen Y., Chun T.T., Chung C.-S., Erickson C.P., Fallon E.A., Le M., Matoso A., Matoso A., Rossi A.-L., Xu S., Xu S.
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai X., Chen X., Cui J., Gu Y., Guo W., Li L., Lin Y., Liu W., Sun Y., Wei B., Xu Q.
Heme oxygenase-1 exerts pro-apoptotic effects on hepatic stellate cells in vitro through regulation of nuclear factor-κB
Chen B., Chen J., Yang H., Zhang L., Zhang X., Zhang X., Zhang Y., Zhao L., Zhao Z., Chen B., Chen J., Yang H., Zhang L., Zhang X., Zhang X., Zhang Y., Zhao L., Zhao Z.
PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis
Ayala A., Chen Y., Chung C.-S., Huang X., Kherouf H., Lepape A., Monneret G., Swan R., Venet F., Wang Y.L., Yuan Z.
Dalby M.J., Tsigkos I.A., Tsimbouri P.M., Salmeron-Sanchez M.
Biomaterials Advances
